Trade Sanofi SA - SANfr CFD

79.34-1.05%
The chart shows the SANfr stock price data over the last 1 day, with a current price of 79.34, a high of 79.68, and a low of 78.86.
Low: 78.86High: 79.68
Sellers:
0%
Buyers:
100%
Past performance is not a reliable indicator of future results. Share prices are indicative and may differ from live market prices.
Trading Conditions
Type
This financial instrument is available for trading through CFDs and Knock-outs.

Knock-out options available only for selected countries.
Learn more about:CFDsKnock-outs
Spread0.17
Long position overnight funding adjustment
Long position overnight funding adjustment

Margin. Your investment
€1,000.00
Overnight funding adjustment
Charges from full value of position
-0.016602 %
(-€0.83)

Trade size with leverage ~ €5,000.00

Money from leverage ~€4,000.00


-0.01660%
Short position overnight funding adjustment
Short position overnight funding adjustment

Margin. Your investment
€1,000.00
Overnight funding adjustment
Charges from full value of position
-0.005621 %
(-€0.28)

Trade size with leverage ~ €5,000.00

Money from leverage ~€4,000.00


-0.00562%
Overnight funding adjustment time21:00 (UTC)
CurrencyEUR
Min traded quantity0.1
Margin20.00%
Stock exchangeFrance
Commission on trade10%
Guaranteed stop premium
A guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.
1%

1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. Close80
Open79.36
1-Year Change-11.39%
Day's Range78.86 - 79.68

Trade Sanofi SA - SANfr CFD

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme. It partners with Alnylam Pharmaceuticals.

Latest shares articles

Doctor with a stethoscope and medical icons in the background.
Sanofi stock forecast: Third-party price targets
Sanofi’s share price reflects the way a large, global pharmaceutical business interacts with markets on a day-to-day basis, responding to company updates, regulatory milestones and wider equity trends.
09:39, 14 January 2026
UniCredit Bank logo on a branch entrance, representing the European banking and financial services group
UniCredit stock forecast: Commerzbank offer, 4 May vote
UniCredit is an Italian banking group listed on the Borsa Italiana, with current coverage centred on its Commerzbank offer, shareholder vote on 4 May 2026, and April 2026 dividend. Past performance is not a reliable indicator of future results. Explore third-party UCG price targets and technicals.
10:37, 10 April 2026
Saipem logo on a mobile device with offshore oil and gas infrastructure, representing the engineering and energy services company
Saipem stock forecast: 2025 results, Subsea7 merger
Saipem is an Italian energy services company whose latest full-year results and planned Subsea7 merger have kept the stock in focus against a volatile backdrop for the wider sector. Past performance is not a reliable indicator of future results. Explore third-party SPM price targets and technicals.
10:23, 10 April 2026
Buzzi Unicem logo on a mobile device with financial charts, representing the cement and construction materials company in the stock market context
Buzzi stock forecast: FY 2025 results, 2026 outlook
Buzzi is an Italian cement producer whose FY 2025 results showed higher sales but lower recurring EBITDA, with 2026 guidance pointing to a slight further contraction. Past performance is not a reliable indicator of future results. Explore third-party BZU price targets and technical analysis.
10:19, 10 April 2026

Read our reviews to find out more about us

Read the feedback from our clients1, whatever their experience level.
2025-07-01
P**** R******

I'm learning the basics of stock investing. This platform is clear and pretty good. I've been using it for over 6 months.

2025-07-01
V***** F******* N***** S****

Great customer service I got to say that. They helped get my account back very fast, after i logged myself out by losing my old email, it was so fast you wouldn’t believe it thank you once again.

2025-06-30
B******

Everything worked as expected from the 1 day. I didn’t have to search how to use the platform, it’s intuitive. The support chat was there when I had a tiny issue.

2025-06-27
G** G******

Capital.com has been great for both learning and trading. The app is clean, fast, and packed with useful tools. Customer support has been solid too. Definitely recommended for beginners and active traders alike.

2025-06-24
R**************

I trade every day and Capital is my beloved home. I also create music and you can always feel when something has been created from the heart. Capital has soul!

2025-06-22
J*** A.

The app is built to make options and figures easy to understand, great for beginners and intermediate traders. Demo accounts are simple to set up. 100:1 leverage is available.

2025-06-22
D******

Deposits and withdrawals work without issues. Very low spreads. No noticeable fees. Easy to follow.

2025-06-19
d*********

I would like to express a huge thank you to Evgeniya Logvinovich, customer service manager. For your attention and heartfelt attitude to your clients.❤️

2025-06-16
f*********

I am extremely happy with this broker. Great spreads, good selection of instruments, well coded toolbox.

2025-05-29
C*********

Love the TV integration. Makes traders life smooth and comfortable.

2025-05-20
G****

I’d been paper trading for 2yrs now, went live and this platform is easy for beginners to understand and navigate all important tools to execute all that I learned. Earning now!

2025-04-29
d******

This application is perfect.. simple, easy to use, run smoothly and fast and it has an accurate graphics.. be careful to use only one credit card and one bank account to prevent any withdrawal problem.. overnight fees and spread variation will be repaid for you by the next month.. I used many application but this is the best one

2025-02-06
N***** B***

User friendly app & interface and good support team. Funds transfer ease & Leverage is an advantage but crypto is highly risky be responsible of your loss limits and risks appetite.

Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.

Ready to join a leading broker?

Join our community of traders worldwide
1. Create your account2. Make your first deposit3. Start trading